PAVmed (PAVM) Liabilities and Shareholders Equity (2015 - 2026)

PAVmed has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $40.2 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 8.38% year-over-year to $40.2 million in Q2 2026; TTM through Jun 2026 was $161.0 million, a 5.62% increase from a year earlier, with the FY2025 full-year figure at $38.8 million, up 26.59% from the prior year.
• Liabilities and Shareholders Equity was $40.2 million for Q2 2026 at PAVmed, up from $38.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $84.3 million in Q1 2022, with the low at $25.0 million in Q3 2024.
• Average Liabilities and Shareholders Equity over 5 years is $49.0 million, with a median of $42.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 74.06% in 2022, then plunged 42.94% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $54.0 million in 2022, then sank by 38.65% to $33.1 million in 2023, then decreased by 7.42% to $30.7 million in 2024, then increased by 26.59% to $38.8 million in 2025, then climbed by 3.61% to $40.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $40.2 million (Q2 2026), $38.8 million (Q4 2025), and $38.1 million (Q3 2025), per Business Quant data.